InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| LPS-EB VacciGrade™ | Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody... | 2022 | PLoS One | Gulyás D. et al. | DOI: 10.1371/journal.pone.0270802 |
| Anti-mTLR2 Detection and Neutralizing mAb | Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody pro... | 2022 | J Autoimmun. | Ning W. et al. | DOI: 10.1016/j.jaut.2022.102860 |
| PGN-SA peptidoglycan preparation | Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody pro... | 2022 | J Autoimmun. | Ning W. et al. | DOI: 10.1016/j.jaut.2022.102860 |
| Mouse TLR2 Reporter HEK293 Cells (NF-κB) | Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody pro... | 2022 | J Autoimmun. | Ning W. et al. | DOI: 10.1016/j.jaut.2022.102860 |
| Mouse Control IgG2a | Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody pro... | 2022 | J Autoimmun. | Ning W. et al. | DOI: 10.1016/j.jaut.2022.102860 |
| PGN-BS peptidoglycan preparation | Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody pro... | 2022 | J Autoimmun. | Ning W. et al. | DOI: 10.1016/j.jaut.2022.102860 |
| pCpGfree-promoter | Identification of TMEM129, encoding a ubiquitin-protein ligase, as an effecto... | 2022 | Arthritis Res Ther. | Brumwell A. et al. | DOI: 10.1186/s13075-022-02882-y |
| Alhydrogel® adjuvant 2% | Virus-like particles displaying conserved toxin epitopes stimulate polyspecif... | 2022 | Sci Rep. | Menzies S.K. et al. | DOI: 10.1038/s41598-022-13376-x |
| NLRP3 inflammasome inhibitor - MCC950 | Dehydroisohispanolone as a Promising NLRP3 Inhibitor Agent: Bioevaluation and... | 2022 | Pharmaceuticals (Basel) | González-Cofrade L. et al. | DOI: 10.3390/ph15070825 |
| Protein L / Agarose | Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as a... | 2022 | Nat Biomed Eng. | Wang Z. et al. | DOI: 10.1038/s41551-022-00902-5 |
| LyoVec™ | Pacritinib Inhibition of IRAK1 Blocks Aberrant TLR8 Signalling by SARS-CoV-2 ... | 2022 | J Innate Immun. | Campbell G.R. et al. | DOI: 10.1159/000525292 |
| SARS-CoV-2 Spike S1 Proteins | A Biosensor Platform for Point-of-Care SARS-CoV-2 Screening. | 2022 | Biosensors (Basel) | Georgas A. et al. | DOI: 10.3390/bios12070487 |
| Human ACE2 Protein | A Biosensor Platform for Point-of-Care SARS-CoV-2 Screening. | 2022 | Biosensors (Basel) | Georgas A. et al. | DOI: 10.3390/bios12070487 |
| Pepinh-TRIF | Activation of TLR-pathway to induce host Th1 immune response against visceral... | 2022 | Heliyon | Pradhan S. et al. | DOI: 10.1016/j.heliyon.2022.e09868 |
| Puromycin | Generation of a live attenuated influenza A vaccine by proteolysis targeting. | 2022 | Nat Biotechnol. | Si L. et al. | DOI: 10.1038/s41587-022-01381-4 |
| Normocin® - Antimicrobial Reagent | High Glucose Induces in HK2 Kidney Cells an IFN-Dependent ZIKV Antiviral Stat... | 2022 | Biomedicines | Reslan A. et al. | DOI: 10.3390/biomedicines10071577 |
| IFN-α/β Reporter HEK 293 Cells | High Glucose Induces in HK2 Kidney Cells an IFN-Dependent ZIKV Antiviral Stat... | 2022 | Biomedicines | Reslan A. et al. | DOI: 10.3390/biomedicines10071577 |
| A549-Dual™ Cells | High Glucose Induces in HK2 Kidney Cells an IFN-Dependent ZIKV Antiviral Stat... | 2022 | Biomedicines | Reslan A. et al. | DOI: 10.3390/biomedicines10071577 |
| Zeocin® | High Glucose Induces in HK2 Kidney Cells an IFN-Dependent ZIKV Antiviral Stat... | 2022 | Biomedicines | Reslan A. et al. | DOI: 10.3390/biomedicines10071577 |
| QUANTI-Blue™ | High Glucose Induces in HK2 Kidney Cells an IFN-Dependent ZIKV Antiviral Stat... | 2022 | Biomedicines | Reslan A. et al. | DOI: 10.3390/biomedicines10071577 |